InMode Ltd. (NASDAQ:INMD) Receives $22.40 Consensus Target Price from Brokerages

InMode Ltd. (NASDAQ:INMD - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $22.40.

Several brokerages have recently commented on INMD. Barclays decreased their price objective on shares of InMode from $27.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 9th. BTIG Research assumed coverage on InMode in a research note on Thursday, October 17th. They issued a "buy" rating and a $25.00 price objective for the company. Finally, Needham & Company LLC reissued a "hold" rating on shares of InMode in a research note on Thursday, October 31st.

Institutional Trading of InMode

Large investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its holdings in shares of InMode by 314.7% in the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company's stock valued at $60,000 after purchasing an additional 2,694 shares in the last quarter. Quarry LP increased its holdings in shares of InMode by 154.3% in the 3rd quarter. Quarry LP now owns 3,781 shares of the healthcare company's stock worth $64,000 after buying an additional 2,294 shares during the last quarter. National Bank of Canada FI raised its position in shares of InMode by 6.2% during the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company's stock valued at $169,000 after buying an additional 579 shares in the last quarter. GW Henssler & Associates Ltd. bought a new position in shares of InMode in the 3rd quarter valued at about $177,000. Finally, DGS Capital Management LLC purchased a new position in InMode in the third quarter worth about $182,000. Institutional investors own 68.04% of the company's stock.

InMode Stock Performance

Shares of NASDAQ INMD traded down $0.11 during trading on Tuesday, hitting $17.17. The company had a trading volume of 588,340 shares, compared to its average volume of 822,453. The stock has a 50 day simple moving average of $17.57 and a 200 day simple moving average of $17.23. The firm has a market capitalization of $1.44 billion, a P/E ratio of 9.29 and a beta of 2.12. InMode has a 12 month low of $14.87 and a 12 month high of $26.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.